DnB Asset Management
CYTK icon

DnB Asset Management’s Cytokinetics CYTK Stock Holding History

DnB Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
12,676
-222
-2% -$15.9K ﹤0.01% 636
2026
Q1 		$850K Buy
12,898
+1,819
+16% +$116K ﹤0.01% 660
2025
Q4 		$704K Buy
11,079
+869
+9% +$54.1K ﹤0.01% 661
2025
Q3 		$561K Sell
10,210
-1,245
-11% -$51.3K ﹤0.01% 667
2025
Q2 		$378K Buy
11,455
+1,021
+10% +$35.5K ﹤0.01% 662
2025
Q1 		$419K Buy
10,434
+1,221
+13% +$56.1K ﹤0.01% 668
2024
Q4 		$433K Buy
9,213
+1,826
+25% +$94.8K ﹤0.01% 670
2024
Q3 		$390K Buy
7,387
+156
+2% +$8.7K ﹤0.01% 668
2024
Q2 		$392K Buy
7,231
+645
+10% +$38.9K ﹤0.01% 663
2024
Q1 		$462K Buy
+6,586
New +$509K ﹤0.01% 657

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DnB Asset Management's CYTK Position: Q2 2026 in Review

DnB Asset Management reduced its Cytokinetics (CYTK) stake by 1.7% in Q2 2026, selling an estimated $15.9K and leaving 12,676 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #636.

DnB Asset Management first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • DnB Asset Management held 12,676 shares of Cytokinetics worth $1.08M as of Q2 2026.
  • DnB Asset Management sold 222 Cytokinetics shares in Q2 2026, an estimated $15.9K.
  • Cytokinetics made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #636 holding.
  • DnB Asset Management first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.